At a Glance
- Company: Celcuity
- Location: United States
- Deal value: Not disclosed
- Focus area: HR-positive, HER2-negative advanced or metastatic breast cancer
- Next steps: Commercial launch is expected late in the third quarter of 2026, with expansion into additional indications planned
What happened?
Celcuity won U.S. FDA approval for Revtorpyk, also known as gedatolisib, marking the company’s first commercial product. The approval is for patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who do not have a PIK3CA mutation and have progressed after at least one line of endocrine therapy in the metastatic setting.
Why does it matter?
The decision gives Celcuity a new entry into the commercial market and adds another targeted option in a setting where treatment choices remain limited. It also reinforces ongoing interest in pathway inhibition for HR+/HER2-negative disease subgroups.
Who’s behind it?
Celcuity is the developer behind Revtorpyk and is now moving from a clinical-stage profile into a branded commercial oncology company. The approval places it alongside established players in the PI3K-pathway space, where biomarker selection is central to use.
How was it achieved?
Revtorpyk’s approval is tied to a specific biomarker-defined population, excluding patients with a PIK3CA mutation. That requirement should help match the drug to the patients most likely to benefit, while also shaping how clinicians incorporate testing into routine care.
What’s next?
Celcuity says it expects launch late in the third quarter of 2026. The company is also continuing development work and plans to expand Revtorpyk into additional indications.